Detection of <i>BRCA1</i>, and <i>BRCA2</i> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting

Detection of <i>BRCA1</i>, and <i>BRCA2</i> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting

Background: Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for patients with metastatic castration-resistant prostate cancer harboring deleterious or suspected deleterious <i>BRCA1</i> and/or <i>2</i> mutations. Identifying patients with prostate cancer harboring...

Full description

Bibliographic Details
Main Authors: Taylor Ryan McFarland, Vinay Mathew Thomas, Roberto Nussenzveig, Georges Gebrael, Nicolas Sayegh, Nishita Tripathi, Kamal Kant Sahu, Divyam Goel, Benjamin L. Maughan, Deepika Sirohi, Neeraj Agarwal, Umang Swami
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Biomedicines
Subjects:
metastatic prostate cancer
BRCA
PARP inhibitor
cancer evolution
cfDNA
next-generation sequencing
Online Access:https://www.mdpi.com/2227-9059/10/12/3170

Similar Items

Similar Items